Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ATOS | US
0.06
1.04%
Healthcare
Diagnostics & Research
30/06/2024
17/04/2026
5.83
5.81
5.94
5.67
Atossa Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen an active metabolite of tamoxifen which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics Inc. in January 2020. Atossa Therapeutics Inc. was founded in 2008 and is headquartered in Seattle Washington.
View LessValue Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
66.8%1 month
85.0%3 months
107.2%6 months
87.1%-
-
2.27
-
-
2.01
-
-
-30.55M
733.16M
733.16M
-
-
-
-
-28.00
22.41
10.28
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.24
Range1M
1.50
Range3M
7.03
Rel. volume
0.81
Price X volume
318.93K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CASTLE BIOSCIENCES INC | CSTL | Diagnostics & Research | 25.05 | 694.81M | 2.00% | n/a | 5.94% |
| Fulgent Genetics Inc | FLGT | Diagnostics & Research | 16.26 | 492.62M | 0.81% | n/a | 1.18% |
| Varex Imaging Corporation | VREX | Diagnostics & Research | 12.01 | 490.74M | 3.53% | 16.69 | 80.92% |
| Myriad Genetics Inc | MYGN | Diagnostics & Research | 5.08 | 461.37M | 1.60% | n/a | 0.00% |
| Pacific Biosciences of California Inc | PACB | Diagnostics & Research | 1.69 | 460.57M | 3.68% | n/a | 187.73% |
| Personalis Inc | PSNL | Diagnostics & Research | 6.73 | 443.75M | 1.05% | n/a | 41.56% |
| Palatin Technologies Inc | PTN | Diagnostics & Research | 22.5 | 439.83M | 7.66% | n/a | -382.57% |
| National Research Corporation | NRC | Diagnostics & Research | 18.03 | 430.40M | 2.33% | 16.76 | 105.03% |
| Delcath Systems Inc | DCTH | Diagnostics & Research | 10.86 | 304.09M | 0.28% | n/a | 133.18% |
| DarioHealth Corp | DRIO | Diagnostics & Research | 7.26 | 218.01M | 3.27% | n/a | 45.01% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.54 | 805.08M | 5.73% | 11.62 | 116.21% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.34 | 732.76M | 5.14% | 65.18 | 77.00% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 17.37 | 724.04M | 5.53% | 42.05 | 64.69% |
| HUYA Inc | HUYA | Media - Diversified | 3.18 | 719.86M | -0.62% | n/a | 0.00% |
| AMC Entertainment Holdings Inc | AMC | Media - Diversified | 1.86 | 672.12M | 15.53% | n/a | -511.14% |
| The Marcus Corporation | MCS | Media - Diversified | 19.82 | 637.68M | 5.99% | n/a | 83.32% |
| Ennis Inc | EBF | Building Products & Equipment | 21.67 | 563.50M | 1.69% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 26.54 | 530.55M | 7.32% | n/a | 1.50% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 23.4 | 388.61M | 6.32% | 34.27 | 26.82% |
| AMC Networks Inc | AMCX | Media - Diversified | 8.77 | 386.74M | 6.56% | 6.32 | 236.34% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 2.01 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 40.09 | - |
| Price to Book | 2.27 | 77.50 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 107.25 | - | Riskier |
| Debt to Equity | - | -14.36 | - |
| Debt to Assets | - | 0.34 | - |
| Market Cap | 733.16M | - | Emerging |